tbuckley/cabot-search huggingface dataset:
Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV metastatic melanoma
Authors: R. E. Hawkins, A. Dangoor, U. Keilholz, D. Schadendorf, A. Harris, C. Ottensmeier, J. Smyth, K. Hoffmnan, R. Anderson, G. Pearce
Journal: Journal of Clinical Oncology (2006)

8030 Background: This trialevaluated the safety, immunogenicity and tumour response of increasing doses of DNA plasmid (DNA.Mel3) and MVA viral vector (MVA.Mel3), containing 7 melanoma epitopes. Methods: 41 HLA-A2 positive stage III/IV melanoma patients with unresectable measurable disease were enrolled. Immunisations were administered three weeks apart with continued MVA.Mel3 boosting in patients with tumour control. Epitope-specific CD8 + T cell responses were evaluated using ex vivo tetramer staining and interferon gamma (IFN-γ) ELISPOT assay. Results: DNA.Mel3 was well tolerated at all doses. Dose-related grade 3 local skin reactions and systemic immune-associated reactions were observed following MVA.Mel3, no reactions led to early study discontinuation. Melan-A tetramer responses were observed in 23/36 (64%) evaluable patients, of which 9/36 showed an IFNγ response to at least one epitope in ELISPOT assay. Seven patients (17%) showed tumour control (PR, MR, or SD &gt;6 months), of which 3/7 patients had associated immune responses, including one with PR &gt; 21 months who underwent extended MVA.Mel3 boosting. Overall median progression free survival was 9 weeks (16 weeks for immune responders). Median overall survival for the intention-to-treat population is 11.7 months with follow up of 16 patients continuing. Conclusions: High dose heterologous PrimeBoost immunisation was safe and stimulated immune responses in &gt;50% of late stage metastatic melanoma patients treated. Tumour control was observed with some evidence of association with immune response. [Table: see text] [Table: see text]
Protein Kinase C Isoform ε Negatively Regulates ADP-Induced Thromboxane Generation by Regulating cPLA2 Activation and Calcium Mobilization In Platelets
Authors: Yamini Bynagari, Parth Lakhani, Kamala Bhavaraju, Jianguo Jin, Mario C Rico, Soochong Kim, Donna S Woulfe, Satya P. Kunapuli
Journal: Blood (2010)
TCT-573 Following Biolimus-Eluting Stenting, No Excess in 3-Year MACE in Diabetic Patients not treated with Insulin
Authors: Marco Roffi, Franz Eberli, Mariano Valdes, Ian Menown, Imad A. Alhaddad, David Hildick-Smith, Keith G. Oldroyd, Erifyli Kalloudi, Ashkan Yazdani, Philip Urban
Journal: Journal of the American College of Cardiology (2015)
Changes in treatment toxicity pattern using the combined treatment of patients with anal canal cancer and early local recurrence results associated with the introduction of new radiation technologies: 3D conformal therapy and intensity modulated radiation therapy
Authors: T. Vuong, S. Faria, T. Ducruet, T. Alcindor, R. Ruo, S. Bucatel, S. Devic
Journal: Journal of Clinical Oncology (2008)

4608 Background: The introduction of targeted radiation therapy delivery allows sparing of normal tissues during radical treatment of patients with head and neck and prostate cancer. This study reports the change in treatment toxicity profile with patients with anal cancer from the era of 3D radiation therapy to the intensity modulated radiation therapy (IMRT) and preliminary data on local recurrence rate. Methods: Sixty-six patients were treated from 2003–2007. Fourty were treated with 3D conformal therapy. The IMRT was introduced in 2006 for twenty-five patients. Dose prescription was standard in both groups: 30 Gy in 15 fractions prescribed to elective iliac and inguinal nodes and 54–59.6 Gy to the tumor bed and involved nodes. Patients were seen weekly during their treatment and toxicity recorded using the NCIC common toxicity criteria version 3. Chemotherapy consisted of 2 cycles of concurrent 5-Fluorouracil (1,000 mg per meter square daily for 4 day in a 24 hour perfusion) with Mitomycin-C (10 mg per meter square) in bolus on day 1 during weeks 1 and 6. Local disease is defined as persistence or tumor either in the primary tumor or pelvic nodes. Results: For 3D-RT and IMRT, we observed respectively: a grade 3 GI toxicity in 2.5% and 4% (p=0.90), a grade 3-skin toxicity rate in 19.2% and 22.5% (p= 0.95) and a grade 3–5 bone marrow toxicity in 17.5% (7/40) and 42% (11/26) (p = 0.03) of patients. Treatment interruption (1 to 3 weeks) was recorded in 24% (6/26) with IMRT as compared to 7.5% (3/40) in the 3D-RT group (p=0.07). There was no significant difference in tumor and patient characteristics between the 2 treatment modalities. At a median follow up time of 29 months in the 3D-RT and 10 months in the IMRT group, we observed a 1-year local recurrence rate of 15.2% and 28.6% (p= 0.40) respectively. Conclusions: New radiation technologies improve GI and skin treatment toxicity profile. However, we observed a significant difference with the use of IMRT at the level of the bone marrow toxicity and trend towards lower local control rate. The use of IMRT should be considered experimental and careful long-term follow up data are warranted. No significant financial relationships to disclose.
Mismatch repair protein expression and Hedgehog signalling pathways in human pancreatic cancer
Authors: A. Bittoni, K. Andrikou, M. Santoni, R. Giampieri, A. Mandolesi, C. Pellei, L. Faloppi, C. Loretelli, A. Lanese, M. Del Prete, E. Maccaroni, M. Bianconi, S. Cascinu
Journal: Annals of Oncology (2015)
Graded prognostic assessment index for colorectal cancer with brain metastases.
Authors: Vidhya Karivedu, Vyshak Alva Venur, Iullia Kim, Samuel T. Chao, John H. Suh, Davendra Sohal, Alok A. Khorana, Xuefei Jia, Manmeet Singh Ahluwalia
Journal: Journal of Clinical Oncology (2015)

2049 Background: Brain metastasis (BM) is a rare but serious neurologic complication of colorectal cancer (CRC). The Disease Specific Graded Prognostic Assessment (DS-GPA) which is based solely on Karnofsky performance scale (KPS) is a commonly used prognostic index in patients with BM. We evaluated DS-GPA and other potential prognostic factors for overall survival (OS) in CRCBM at our institution. Methods: With IRB approval, the Cleveland Clinic Brain Tumor and Neuro-Oncology Center's database was used to identify CRCBM patients treated between 2002 and 2014. OS from the diagnosis of CRC BM was the primary endpoint. Cox proportional hazards models with stepwise variable selection were used to identify independent prognostic factors. Results: Ninety four patients with median age of 60 years (range; 32-87), were included for analysis. KPS was 90-100 in 35 patients (38%), 70-80 in 35 (39%) and <70 in 20 (23%) patients. Single BM was noted in 53 (56%), 2-3 BM in 25 (27%) and >3 BM in 16 (17%) patients. Eighty nine patients (95%) were symptomatic at diagnosis. Forty nine(52%) patients had supratentorial BM, 25(25%) had infratentorial BM and 20 (21%) had both supra-and infratentorial BM at diagnosis. Initial therapy included whole brain radiation (WBRT) in 31 (33%), stereotactic radiosurgery (SRS) in 22(23%), WBRT + SRS in 11(12%), surgery (S) in 2 (2%), S+SRS in 6 (6%), S+WBRT in 14(15%), S+SRS+WBRT in 1(1%), while 2 patients received only chemotherapy and 5 underwent observation. Median OS from diagnosis of BM was 5.5 months (95% C.I. 3.5-7.5). In multivariate analysis KPS and number of BM were independent predictors of OS. Combining these factors a revised GPA with three groups was defined: unfavorable (total points ≤3), intermediate (4-5), and favorable (≥6 points) with median OS of 2.8, 6.1 and 14.7 months, respectively. Conclusions: A revised DS-GPA for CRCBM based on KPS (performance status) and number of BM is proposed. Factors No. of points Hazard ratio P valve Number of BM 1.27(1.02-1.59) 0.032 1 3 2 2 3 1 >3 0 Colon cancer specific GPA (KPS) 0.78(0.63-1.59) 0.015 100 4 90 3 80 2 70 1 <70 0 Revised GPA No. Points Median OS (mo) Unfavorable ≤3 2.8 Intermediate 4-5 6.1 Favorable ≥6 14.7
Post-transplant lymphoproliferative disorder in adult lung transplant recipients: A report on twenty-seven patients
Authors: S. Stein, J. Misleh, V. Ahya, R. Kotloff, D. Hadjiliadis, J. Christie, A. Loren, S. Schuster, E. A. Stadtmauer, D. E. Tsai
Journal: Journal of Clinical Oncology (2008)

19521 Background: Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of pharmacologic immunosuppression associated with organ transplantation. Lung transplant patients are known to be at particularly high risk for PTLD due to their heavy immunosuppression and difficult to treat due to the risk of allograft rejection, yet little data is available on their management and outcome. Methods: We report a retrospective case series on the diagnosis, treatment and outcome of PTLD in adult lung transplant recipients. Results: From 1991 to 2006, 27(5.3%) of the 502 lung transplant recipients at our institution developed PTLD. The median age at transplantation was 51.5 years(range 21–65 years) with a median time from transplant to PTLD diagnosis of 33.7 months(range 1–174 months). Most cases had an elevated LDH(86%) and were EBV-positive(85%). All PTLD cases were of B cell origin with 55% polymorphic and 45% monomorphic histology. Of the cases tested(n=14), 64% were monoclonal. PTLD was frequently diagnosed in the transplanted lung(56%) and gastrointestinal tract(26%). Three patients were diagnosed at autopsy, while the remaining 24 received therapy. Eight patients were initially treated with reduced immunosuppression (RI) alone, but only 3(38%) obtained a complete response (CR). Rituximab (R) was used alone (n=2) or in combination with RI (n=9) with 6 (55%) patients attaining a CR. The remaining 5 patients from the 24 patients receiving induction therapy for PTLD were given other treatments. With an average follow-up of 28 months (range 1–130 months), 81% of patients have died. However, only 18% of deaths were directly related to progressive PTLD. The remaining 17 deaths were due to: infection unrelated to PTLD treatment (15%), multi-organ failure (7%), allograft failure not due to RI (30%), stroke (4%), and renal failure (4%). Most deaths can be attributed to disease specific and posttransplant complications rather than PTLD. Conclusions: Although an unfortunate diagnosis, PTLD is responsive to therapy, particularly reduced immunosuppression and rituximab. Due to the high frequency of pulmonary and gastrointestinal extranodal involvement, PTLD should be considered in lung transplant patients with lesions in these organ systems. No significant financial relationships to disclose.
Outcome by Treatment Including An Intensified Consolidation Program with Dose-Escalated Doxorubicin for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL): A Study by the Japan Adult Leukemia Study Group (JALSG ALL97 study).
Authors: Itsuro Jinnai, Tohru Sakura, Motohiro Tsuzuki, Yasuhiro Maeda, Noriko Usui, Masayuki Kato, Hirokazu Okumura, Yasunori Ueda, Yuji Kishimoto, Fumiharu Yagasaki, Jin Takeuchi, Masako Iwanaga, Yasushi Miyazaki, Shuichi Miyawaki, Kazunori Ohnishi, Tomoki Naoe, Ryuzo Ohno
Journal: Blood (2009)
Daily concurrent chemoradiotherapy with docetaxel (DOC) and cisplatin (CDDP) using superselective intra-arterial infusion (HFT method) via superficial temporal artery for T3 and T4 head and neck cancer—Possibility of organ preservation in advanced head and neck cancer
Authors: K. Mitsudo, T. Shigetomi, H. Nishiguchi, N. Yamamoto, T. Fukui, H. Furue, M. Saito, M. Ueda, I. Tohnai
Journal: Journal of Clinical Oncology (2008)

17044 Background: Superselective intra-arterial chemotherapy via a superficial temporal artery (HFT method) has become feasible for daily concurrent radiotherapy and chemotherapy for head and neck cancer. We used this novel method for head and neck cancer, and evaluated its efficacy. Treatment consisted of superselective intra-arterial infusions (docetaxel 60 mg/m2, cisplatin 100 mg/m2) and concurrent radiotherapy (40 Gy) for four weeks as preoperative therapy. Thirty-five patients with stage III and IV oral cancer underwent surgery after this treatment, of whom pathological complete response (CR) was obtained in 31 (88.6%). In this study, the possibility of organ preservation in cases of advanced head and neck cancer was evaluated based on this result. Methods: T3 and T4 head and neck cancer were eligible for evaluation. External irradiation was performed five times a week at 2 Gy per fraction. The total dose of docetaxcel (DOC) was 60 mg/m2 (15 mg/m2/week), and that of cisplatin (CDDP) was 100 mg/m2 (5 mg/m2/day). This concurrent chemoradiotherapy was conducted for four weeks, and the subjects enrolled in the present study were 30 patients with T3 or T4 patients whose clinical diagnosis was CR based on MRI, CT scan. Following examination together with a radiation oncologist, intra-arterial chemoradiotherapy was continued in these patients for an additional 1 or 2 weeks. Total dose of DOC was 60 mg/m2 and CDDP was 125 to 150 mg/m2. Results: Twenty-four patients (80.0%) were disease free in the primary sites. Local recurrence was observed in six patients (20.0%), all of whom underwent salvage operation, and the final local control rate was 96.7% (29 of 30 cases). Two patients (6.6%) died, one of progression of the primary lesion, and one of pulmonary metastasis. The estimated 1-year and 3-year survival rates by Kaplan-Meier’s method are 96.6% and 82.8%, respectively. No major complications such as cerebral infarctions or other neurological complications developed in any patient. Conclusions: This method can preserve organs and minimize functional disturbance, thus contributing to patients’ QOL. No significant financial relationships to disclose.
Female circumcision as a public health issue. by Nahid Toubia
Authors: Nahid Toubia
Journal: New England Journal of Medicine (1994)

tag=1 data=Female circumcision as a public health issue. by Nahid Toubia

tag=2 data=Toubia, Nahid

tag=3 data=The New England Journal of Medicine,

tag=4 data=331

tag=5 data=11

tag=6 data=15 September 1994

tag=7 data=712-716.

tag=8 data=WOMEN

tag=10 data=This article reviews the common types of circumcision, their complications, and the challenges in giving appropriate care to circumcised women.  It also gives a brief review of the legal and ethical issues that include consideration of existing and expected pieces of legislation and what they mean to the medical profession. Provided by MICAH.

tag=11 data=1995/1/1

tag=12 data=95/0014

tag=13 data=CAB
Absolute Lymphocyte Count Is Independent of the Anaplastic Lymphoma Kinase and Predicts Survival in Primary Anaplastic Large Cell Lymphoma.
Authors: Luis F. Porrata, Kay Ristow, Thomas E. Witzig, Thomas M. Haberman, David J. Inwards, Stephen M. Ansell, Ivana N. Micallef, Patrick B. Johnston, Joseph Colgan, William L. White, Svetomir N. Markovic
Journal: Blood (2007)
TCT-89 Renal Sympathetic Denervation in Treatment Resistant Essential Hypertension. A Sham-Controlled, Double-blinded Randomized Trial (ReSET trial)
Authors: Ole N. Mathiassen, Jesper N. Bech, Niels Henrik Buus, Kent L. Christensen, Henrik Vase, Jannik B. Bertelsen, Rickers Hans, Ulla Kampmann, Morten E. Pedersen, Ole L. Pedersen, Christian D. Peters, Per L. Poulsen, Jens F. Lassen, Klavs Würgler, Hans Erik Boetker, Pauline Schroeder, Erling B. Pedersen, Anne Kaltoft
Journal: Journal of the American College of Cardiology (2015)
Samarium-<sup>153</sup>Sm-EDTMP and zoledronic acid present synergistic action and are able to control pain and significantly improve QoL in elderly patients with MM. (Results of a phase II trial and 19 months follow up)
Authors: F. Iuliano, S. Molica, E. Abruzzese, A. Peta, A. Toraldo, S. Palermo
Journal: Journal of Clinical Oncology (2004)

6737 Background: Previously, we reported results on the association of samarium-153 Ethilene Diamine Tetramethylene Phosphonate (153Sm-EDTMP) and zoledronic acid in the treatment of symptomatic refractory elderly multiple myeloma patients.(Proc.ASCO 2003).In order to expand on these observations we would like to provide with detailed follow-up data obtained in a series accounting now for 8 patients. Methods: Inclusion criteria: refractory MM diagnosis on pain control.Normal liver and renal function.No cytopenia. Median age was 78.5 years (range 70–81 yrs) M:F=5:3;ECOG PS >= 2; median time from diagnosis to Rx = 2 years (range 4–36 months); IgGλ #3 pts, IgGκ #4 pts, IgAκ #1 pt M-component and DS stage IIIA for all.#3 received >2 previous chemotherapeutic treatments .None of the patients was allowed to receive additional treatment during Rx. 99mTc-MDP bone scans and 153Sm-EDTMP gamma camera imaging were equivalent Treatment consisted of zoledronic acid (4mg) every 28 days, while 2GBq of 153Sm-EDTMP was given at enrolment and allowed to be repeated when the disease became symptomatic.All 8 patients complained of severe, persistent pain, requiring a combination of non-oppioid analgesics. Patients were asked to quantify their pain using a visual analogue scale (0–10) Results: :@ baseline, the median pain-rate was 7 (range 7–9). After treatment the median pain rate was reduced to 2 (range 0–3) with no need for analgesics (P=0.06) with a median FU time of 14 months (range 6–19 ). Two patients had transient grade 2 WHO hematologic toxicity. Only one patient suffered for pain flares.Interestingly, M-component decreased more than 25% in 4/8 patients and was still stable Median survival was 36 months ( range 13–50)). The median time to 2nd 153Sm-EDTMP infusion was 6.5 months and the median survival time from the first Rx was 15 months . Conclusions: Our results support the idea that treatment with 153Sm-EDTMP and zoledronic acid is synergistic and has a significant impact on the outcome of elderly myeloma patients. No significant financial relationships to disclose.
Prospective validation of the new graded prognostic assessment scale for brain metastases: A multicenter study.
Authors: S. Villa, D. C. Weber, C. Moretones, A. Manes, P. Puyalto, P. Cuadras, J. Bruna, E. Verger, F. Graus, C. Balana
Journal: Journal of Clinical Oncology (2010)

2074 Background: Prognostic indexes are useful to guide tailored treatment strategies for cancer patients (pts) with brain metastasis (BM). We evaluated the new Graded Prognostic Assessment (GPA) scale in a prospective validation study. Methods: A total of 285 BM (n = 85 with synchronous BM) pts, accrued between 2000 and 2009, were included in this analysis. Median age was 60.1 ± 12.0 years. The median KPS and number of BM was 70 and 3, respectively. The majority of primary tumours were lung (53%), or breast (17%) cancers. Twenty-eight percent of the cohort had no extracranial metastasis (ECrM). Forty percent and 44% of patients presented with stable and progressive disease, respectively. NED was found in another 16% of patients. Treatment was administered to 255 (89.5%) patients. Only a minority of patients could be classified prospectively in a favourable prognostic class: GPA 3.5-4: 3.9%; recursive partitioning analysis (RPA) 1, 8.4% and Basic Score for BM (BSBM) 3, 9.1%. Median follow-up (FU) was 5.2 ± 4.7 months. Results: During the period of FU, 225 (78.9%) patients died. The 6 months- and 1 year-OS was 36.9% and 17.6%, respectively. On univariate analysis, improved OS was found to be significantly associated with KPS (p < 0.001), GPA (p < 0.001), RPA (p < 0.001), BSBM (p < 0.001), treatment (p < 0.001), no ECrM (p = 0.004), control of the primary tumor (p = 0.009), number of BM (≤ 3 vs. > 3; p = 0.017) and type of primary cancer (p = 0.034). On multivariate analysis, only treatment (p < 0.001), RPA (p = 0.002), GPA (p = 0.004) and BSBM (p = 0.03) retained statistical significance. Conclusions: Our data suggest that the new GPA index is as prognostic as the RPA scale. This score avoids systemic disease status evaluation. No significant financial relationships to disclose.
TCT-471 Utility of the ACC/AHA Lesion Classification in the Modern Era of Percutaneous Coronary Intervention
Authors: Matias Yudi, Peter J. Scott, Omar Farouque, Jay Ramchand, Nicholas Jones, Cheng Yee Goh, Christopher Reid, Stephen J. Duffy, Angela Brennan, Dharsh Fernando, Andrew Ajani, David Clark
Journal: Journal of the American College of Cardiology (2015)
Development of an Allele-Specific Minimal Residual Disease Assay for Patients with Juvenile Myelomonocytic Leukemia-Moving beyond Clinical Assessment.
Authors: Sophie Archambeault, Ayami Yoshimi, Christian Kratz, Miriam Reising, Alexandra Fischer, Peter Noellke, Franco Locatelli, Petr Sedlacek, Christian Flotho, Marco Zecca, Peter Dean Emanuel, Robert Castleberry, Charlotte Marie Niemeyer, Peter Bader, Mignon Loh
Journal: Blood (2006)
Comparaison of Serum Free Light Chain Measurement with Classical Methods for the Evaluation of Patients with Immunoproliferative Diseases under Treatment.
Authors: Florence Cattan, Richard Delarue, Fadi Fakhouri, Aicha Abbas, Bertrand Arnulf, David Ghez, Francoise Aucouturier, Olivier Hermine, Marie-Alexandra Alyanakian
Journal: Blood (2005)
Evaluation of the Oncohaematologic Pathology of Two Oncologics Centers of Buenos Aires, Argentina in the Period between 1995–2005; a Total of 1884 Cases.
Authors: Marta O. Dragosky, Isabel Annetta, Viviana Alvarellos4, Laura Devotto5, Patricia Luchetta6, Marisa Marquez7, Susana Alcaraz
Journal: Blood (2005)
TCT-639 TAVI in local anesthesia without general anesthesia or deep sedation, a single center comparison of 30-day clinical outcome between balloon-expandable and self-expandable valves
Authors: Wolfgang Bocksch, Martin Steeg, Patrik Htun, Michael Droppa, Tobias Geisler, Meinrad Gawaz, Suzanne Fateh-Moghadam
Journal: Journal of the American College of Cardiology (2015)
Mucins and carbohydrates associated antigens expression in colorectal cancer patients
Authors: A. O. Zwenger, C. Andrea, E. Lacunza, M. Rabassa, S. Amada, M. V. Croce, J. Iturbe, P. Leone, J. A. Lacava, M. R. Machiavelli
Journal: Journal of Clinical Oncology (2008)

15072 Background: Local and metastatic recurrence are frequent events in colorectal cancer. Certain indicators such as glycoproteins and carbohydrate antigens in primary tumors may be useful for early detection of disease dissemination. The purpose of this study was to evaluate the expression of mucins and carbohydrates associated antigens in normal, benign and malignant colorectal tissue samples. Methods: Immunohistochemical analysis was performed on 114 colorectal carcinoma samples, 22 adenomas and 35 normal colorectal mucosa specimens. Different monoclonal antibodies (MAbs) were studied: anti-MUC2 mucin (PMH1), MUC1 (CT2 and HMFG2) and anti-alpha 1 glycoprotein (AGP). We also analyzed carbohydrate antigens such as Lewis x (KM380), sialyl Lewis x (KM93), Lewis y (C14) and sialyl Lewis a. Immunohistochemistry was performed following standard procedures with antigenic retrieval. A multivariate statistical analysis with Principal Component (PCA) and Kendall-tau correlation was applied. Results: Malignant samples expressed MUC2 in 84.4% of cases, MUC1 in 70%, AGP in 68%, Lewis x in 57%, sialyl Lewis x in 31%, Lewis y in 43% and sialyl Lewis a in 88.5%. All antigens were also present in benign and normal tissues although progression to malignancy showed an increased expression of Lewis y, sialyl Lewis x and AGP and a decreased expression of MUC2 and Lewis x. In malignant samples, MUC1 mucin expression was increased compared to benign and normal tissues (P<0.04). Also, a statistically significant correlation between sialyl Lewis x and Lewis y (tau=0.4606) was found in colorectal cancer. Conclusions: This study demonstrates that MUC1 mucin, AGP, Lewis y and sialyl Lewis x are over expressed in colorectal cancer, whereas a decrease mainly in Lewis x and MUC2 mucin is observed. Further studies are needed in order to correlate these findings with clinical outcomes. No significant financial relationships to disclose.
Type 3c (pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer
Authors: Phil A Hart, Melena D Bellin, Dana K Andersen, David Bradley, Zobeida Cruz-Monserrate, Christopher E Forsmark, Mark O Goodarzi, Aida Habtezion, Murray Korc, Yogish C Kudva, Stephen J Pandol, Dhiraj Yadav, Suresh T Chari
Journal: The Lancet. Gastroenterology & hepatology (2016)